Early treatment of migraine attacks with triptans: a strategy to enhance outcomes and patient satisfaction?

References

• Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd Edition. Cephalalgia24(Suppl. 1), 9–160 (2004).
   Google Scholar
• Silberstein SD, Saper JR, Freitag FG. Migraine: Diagnosis and Treatment. In: Wolff´s Headache and Other Head Pain. Silberstein SD, Lipton RB, Dalessio DJ (Eds), Oxford University Press, NY, USA 121–237 (2001).
   Google Scholar
• Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache41, 646–657 (2001).
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia2, 519–522 (2003).
   Google Scholar
• Lanteri-Minet M, Valade D, Geraud G, Chautard MH, Lucas C. Migraine and possible migraine: results of FRAMIG 3, a French nation-wide survey carried out according to the 2004 IHS classification. Cephalalgia25, 1146–1158 (2005).
   PubMed Web of Science ®Google Scholar
• Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch. Intern. Med.10, 255–259 (1999).
   Google Scholar
• Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF. Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia23, 441–450 (2003).
   PubMed Web of Science ®Google Scholar
• D’Amico D, Usai S, Grazzi L et al. The impact of primary headaches on patients’ lives: Italian experience with the MIDAS and the SF-36 questionnaires. Headache Care1, 123–128 (2004).
   Google Scholar
• Dueland AN, Leira R, Burke TA, Bolge S. The impact of migraine on work, family, and leisure among young women – a multinational study. Curr. Med. Res. Opin.20, 1595–1604 (2004).
   PubMed Web of Science ®Google Scholar
• Solomon GD, Santanello N. Impact of migraine and migraine therapy on productivity and quality of life. Neurology55(Suppl. 2), S29–S36 (2000).
   PubMedGoogle Scholar
• Dueland AN, Leira R, Cabelli ST. The impact of migraine on psychological well-being of young women and their communication with physicians about migraine: a multinational study. Curr. Med. Res. Opin.21, 1297–1305 (2005).
   PubMed Web of Science ®Google Scholar
• Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and labor costs of migraine in the US. Pharmacoeconomics2, 67–76 (1992).
   PubMedGoogle Scholar
• Terwindt GM, Ferrari MD, Tijhuis M, Groenen SM, Picavet HS, Launer LJ. The impact of migraine on quality of life in the general population: the GEM study. Neurology55, 624–629 (2000).
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology55, 754–762 (2000).
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Lipscombe S, Sender J, Rees T, Watson D. Migraine in primary care advisors. New guidelines for the management of migraine in primary care. Curr. Med. Res. Opin.18, 414–439 (2002).
   PubMed Web of Science ®Google Scholar
• Humphrey PPA. How it started. Cephalalgia21, 2–5 (2001).
   PubMed Web of Science ®Google Scholar
• Humphrey PP. 5-Hydroxytryptamine and the pathophysiology of migraine. J. Neurol.238(Suppl. 1), S38–S44 (1991).
   PubMed Web of Science ®Google Scholar
• Saxena PR, Tfelt-Hansen P. Triptans, 5HT1B/1D receptor agonists in the acute treatment of migraines. In: The Headaches. Third Edition. Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA (Eds), Lippincott Williams & Wilkins, Philadelphia, USA, 469–503 (2006).
   Google Scholar
• Tfelt-Hansen P. A comparative review for pharmacology, pharmacokinetics and efficacy of triptans in migraine. Drugs6, 1259–1287 (2000).
   Google Scholar
• Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia22, 633–658 (2002).
   PubMed Web of Science ®Google Scholar
• Brandes JL. Global trends in migraine care: results from the MAZE survey. CNS Drugs16(Suppl. 1), 13–18 (2002).
   Google Scholar
• Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache39(Suppl. 2), S20–S26 (1999).
   Google Scholar
• Cady RK, Lipton RB, Hall C, Stewart WF, O’Quinn S, Gutterman D. Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache40(10), 792–797 (2000).
   PubMed Web of Science ®Google Scholar
• Cady RK, Sheftell F, Lipton RB et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin. Ther.22(9), 1035–1048 (2000).
   PubMed Web of Science ®Google Scholar
• Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache42, 28–31 (2002).
   PubMed Web of Science ®Google Scholar
• Mathew N. Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache43, 1075–1079 (2003).
   PubMed Web of Science ®Google Scholar
• Winner P, Mannix LK, Putnam DG et al. Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo controlled studies. Mayo Clin. Proc.78, 1214–1222 (2003).
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Massiou H, Lainez JM, Caborrocas X. Almotriptan improves response rates when treatment is within 1 hour of migraine onset. Headache44, 318–322 (2004).
   PubMed Web of Science ®Google Scholar
• Klapper J, Lucas C, Rosio O, Charlesworth B on behalf of the ZODIAC study group. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia24, 918–924 (2004).
   PubMed Web of Science ®Google Scholar
• Scholpp J, Schellenberg R, Moeckesch B, Banik N. Early treatment of a migraine attack while pain is still increases the efficacy of sumatriptan. Cephalalgia24, 925–933 (2004).
   PubMed Web of Science ®Google Scholar
• Carpay J, Schoenen J, Ahmad F, Kinrade F, Boswell D. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clin. Ther.26, 214–223 (2004).
   PubMed Web of Science ®Google Scholar
• Cady R, Elkind A, Goldstein J, Keywood C. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr. Med. Res. Opin.20(9), 1465–1472 (2004).
   PubMed Web of Science ®Google Scholar
• Mathew NT, Kailasam J, Meadors L. Early treatment of migraine with rizatriptan: a placebo-controlled study. Headache44(7), 669–673 (2004).
   PubMed Web of Science ®Google Scholar
• Brandes JL, Kudrow D, Cady R, Tiseo PJ, Sun W, Sikes CR. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia25(9), 735–742 (2005).
   PubMed Web of Science ®Google Scholar
• Winner P, Landy S, Richardson M, Ames M. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials. Clin. Ther.27, 1785–1794 (2005).
   PubMed Web of Science ®Google Scholar
• Lofland JH, Johnson NE, Batenhorst AS, Nash DB. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective. Arch. Intern. Med.159(18), 2228 (1999).
   Google Scholar
• Dasbach EJ, Carides GW, Gerth WC, Santanello NC, Pigeon JG, Kramer MS. Work and productivity loss in the rizatriptan multiple attack study. Cephalalgia20(9), 830–834 (2000).
   PubMed Web of Science ®Google Scholar
• Santanello NC, Polis AB, Hartmaier SL, Kramer MS, Block GA, Silberstein SD. Improvement in migraine-specific quality of life in a clinical trial of rizatriptan. Cephalalgia17(8), 867–872 (1997).
   PubMed Web of Science ®Google Scholar
• Lainez MJ, Lopez A, Pascual AM. Effects on productivity and quality of life of rizatriptan for acute migraine: a workplace study. Headache45(7), 883–890 (2005).
   PubMed Web of Science ®Google Scholar
• Colman SS, Brod MI, Krishnamurthy A, Rowland CR, Jirgens KJ, Gomez-Mancilla B. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin. Ther.23(1), 127–145 (2001).
   PubMed Web of Science ®Google Scholar
• Biddle AK, Shih YC, Kwong WJ. Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine. Pharmacotherapy20, 1356–1364 (2000).
   PubMed Web of Science ®Google Scholar
• Ceballos Hernansanz MA, Sanchez Roy R, Cano Orgaz A, Lopez-Gil A, START 10 Study Group. Migraine treatment patterns and patient satisfaction with prior therapy: a substudy of a multicenter trial of rizatriptan effectiveness. Clin. Ther.25(7), 2053–2069 (2003).
   PubMed Web of Science ®Google Scholar
• Powers C, Szeto S, Pangtay D, Bort T, Cervi M, Cady R. Evaluation of migraineurs’ preferences for naratriptan over conventional first-line agents. Arch. Fam. Med.9(8), 753–758 (2000).
   PubMedGoogle Scholar
• Goadsby PJ, Dodick DW, Ferrari MD, McCrory DC, Williams P. TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management. Acta Neurol. Scand.110(3), 137–143 (2004).
   PubMed Web of Science ®Google Scholar
• Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia20, 554–560 (2000).
   PubMed Web of Science ®Google Scholar
• Ferrari MD. Should we advise patients to treat migraine attacks early? Cephalalgia24, 915–918 (2004).
   PubMed Web of Science ®Google Scholar
• Cady RK, Sheftell F, Lipton RB, Kwong WJ, O’Quinn S. Economic implications of early treatment of migraine with sumatriptan tablets. Clin. Ther.23, 284–291 (2001).
   PubMed Web of Science ®Google Scholar
• Halpern MT, Lipton RB, Cady RK, Kwong WJ, Marlo KO, Batenhorst AS. Costs and outcomes of early versus delayed migraine treatment with sumatriptan. Headache42, 984–999 (2002).
   PubMed Web of Science ®Google Scholar
• Kwong WJ, Taylor FR, Adelman JU. The effect of early intervention with sumatriptan tablets on migraine-associated productivity loss. Occup. Environ. Med.47(11), 1167–1173 (2005).
   Web of Science ®Google Scholar
• Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann. Neurol.47(5), 614–624 (2000).
   PubMed Web of Science ®Google Scholar
• Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain89, 107–110 (2001).
   PubMed Web of Science ®Google Scholar
• Burstein R, Jakubowski M. Analgesic triptan action in a animal model of intracranial pain: a race against the development of central sensitization. Ann. Neurol.55(1), 27–36 (2004).
   PubMed Web of Science ®Google Scholar
• Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann. Neurol.55, 19–26 (2004).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME, Rush SR et al. Migraine practice patterns among neurologists. Neurology62(11), 1926–1931 (2004).
   PubMed Web of Science ®Google Scholar
• Foley KA, Cady R, Martin V et al. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. Headache45(5), 538–545 (2005).
   PubMed Web of Science ®Google Scholar
• Moschiano F, D’Amico D, Allais G et al. Early triptan intervention in migraine: an overview. Neurol. Sci.26(Suppl. 2), 108–110 (2005).
   PubMed Web of Science ®Google Scholar
• Stang PE, VonKorff M. The diagnosis of headache in primary care: factors in the agreement of clinical and standardized diagnoses. Headache34, 138–142 (1995).
   Web of Science ®Google Scholar
• Kavuk I, Katsarava Z, Selekler M et al. Clinical features and therapy of medication overuse headache. Eur. J. Med. Res.9(12), 565–569 (2004).
   PubMed Web of Science ®Google Scholar
• Saper JR, Dodick D, Gladstone JP. Management of chronic daily headache: challenges in clinical practice. Headache45(Suppl. 1), S74–S85 (2005).
   Google Scholar
• Meletiche DM, Lofland JH, Young WB. Quality-of-life differences between patients with episodic and transformed migraine. Headache41, 573–578 (2001).
   PubMed Web of Science ®Google Scholar
• Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache43, 336–342 (2003).
   PubMed Web of Science ®Google Scholar
• D’Amico D, Grazzi L, Usai S, Rigamonti A, Curone M, Bussone G. Disability pattern in chronic migraine with medication overuse: a comparison with migraine without aura. Headache45(5), 553–560 (2005).
   PubMed Web of Science ®Google Scholar
• Fruhstorfer H, Lindblom U, Schmidt WC. Method for quantitative estimation of thermal thresholds in patients. J. Neurol. Neurosurg. Psychiatry39, 1071–1075 (1976).
   PubMed Web of Science ®Google Scholar
• Jakubowski M, Silberstein S, Ashkenazi A, Burstein R. Can allodynic migraine patients be identified interictally using a questionnaire? Neurology65, 1419–1422 (2005).
   PubMed Web of Science ®Google Scholar